You are here:

Plegridy approved for relapsing remitting MS in England

Published on

NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing remitting MS.

In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on Plegridy and has now completed a separate appraisal.

The MS Trust contributed throughout the process.

We are pleased that NICE has approved Plegridy for people with relapsing remitting MS. We were able to make a strong case to NICE thanks to those of you who told us about your experiences of taking this treatment and the importance of having a greater choice of disease modifying drugs.

- David Martin, Chief Executive Officer, MS Trust

Plegridy (peginterferon beta 1a) is a disease modifying drug for relapsing remitting MS which you inject once a fortnight. Plegridy is already approved for use in Scotland and Wales.

Find out more about Plegridy.

Find out more

The ADAMS project

The ADAMS project

25/05/2022 - 00:00

Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.

Five minutes with a fundraiser: Huxley's Miles for MS

Five minutes with a fundraiser: Huxley's Miles for MS

20/07/2022 - 00:00

In May 2022, eight-year-old Huxley was inspired to take on his first Miles for MS challenge. Here, Huxley tells us all about his motivation and how he ended up creating a song from the experience!

When is a relapse not a relapse?

When is a relapse not a relapse?

20/07/2022 - 00:00

Have you ever been told you’re having a pseudo relapse? In this blog Helena from the MS Trust info and engagement team looks into some  different situations, when a relapse perhaps isn't a relapse after all.

Print this page